C-Bridge Capital and Tasly Holding, a TCM company, have teamed up to invest $150 million in two young China biopharmas, which will be merged into a single entity as part of the investment. The two existing companies are Shanghai’s Tianjing Biopharma and Tianjin’s Tianzhenshi Biotechnology. The merged companies, whose new name was not disclosed, will jointly hold twelve antibody drug candidates. With $700 million under management, C-Bridge led a $100 million investment in HCV company Ascletis two months ago.
